Advanced in Restrictive Cardiomyopathy (RCM)

Patrizio Lancellotti

Liege, WAL, BE 
Advanced in Restrictive Cardiomyopathy (RCM)
Liege, WAL, BE 
OverviewLocationsClinical Research

Overview

Patrizio Lancellotti practices in Liege, Belgium. Mr. Lancellotti is rated as an Advanced expert by MediFind in the treatment of Restrictive Cardiomyopathy (RCM). His top areas of expertise are Aortic Valve Stenosis, Mitral Valve Regurgitation, Endocarditis, Transcatheter Aortic Valve Replacement (TAVR), and Embolectomy.

His clinical research consists of co-authoring 751 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Restrictive Cardiomyopathy (RCM).

Gender
Male

Locations

Liege, WAL, Belgium
Other Locations
Domaine Universitaire Du Sart Tilman B.35 4000 Liège, Sart Tilman, WAL 4000, Belgium
Belgium
CHU Sart Tilman, Liège. UZB
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Rivaroxaban, Acetylsalicylic acid
Study Phase: Phase 4
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Clinical PeRformance EVAluatIon of a New Medtronic Coronary Drug-Coated BaLloon Catheter for the Treatment of De Novo Lesions, In-Stent Restenosis and Small Vessel Disease in Coronary Arteries: The PREVAIL Study
A Clinical PeRformance EVAluatIon of a New Medtronic Coronary Drug-Coated BaLloon Catheter for the Treatment of De Novo Lesions, In-Stent Restenosis and Small Vessel Disease in Coronary Arteries: The PREVAIL Study
Enrollment Status: Completed
Publish Date: September 30, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 3 Less Clinical Trials

749 Total Publications

Recent advances in cardiovascular pathophysiology, biomarkers, and therapeutic strategies: highlights from Acta Cardiologica.
Recent advances in cardiovascular pathophysiology, biomarkers, and therapeutic strategies: highlights from Acta Cardiologica.
Journal: Acta cardiologica
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lancellotti's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 75 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile